Nucleic acids encoding endotheliases, endotheliases and uses thereof

• US 7,276,364 B1
• Filed: 11/20/2000
• Issued: 10/02/2007
• Est. Priority Date: 11/18/1999
• Status: Expired due to Term

• Current Assignee: Dendreon Pharmaceuticals, Inc. (Ya Fei Yuan,)
• Original Assignee: Dendreon Corporation (Bausch Health Cos., Inc.)
• Inventors: Madison, Edwin L., Ong, Edgar O.
• Primary Examiner(s): Rao; Manjunath
• Application Number:
  US09/717,473
• Time in Patent Office: 2,507 Days
• Field of Search: 435/183, 435/188, 435/195, 435/212, 435/213, 435/217, 435/218, 435/219, 435/226, 435/4, 435/6, 435/23.24, 435/69.1, 435/252.3, 435/320.1, 435/200, 435/440, 530/412, 530/419, 530/421, 530/810, 530/812, 530/815, 530/816, 530/827, 530/23.2, 530/23.5, 530/23.7
• US Class Current: 435/219
• CPC Class Codes: A61P 1/02 Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 41/00 Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C12N 9/6424 Serine endopeptidases (3.4.21)

Abstract

Provided herein are endotheliases and portions, particularly, the protease domains, and nucleic acids that encode the endotheliases. The endotheliases are transmembrane proteases expressed in endothelial cells. The nucleic acids and encoded proteins and protease domain portions thereof are used in a variety of prognostic, diagnostic, therapeutic and screening methods, including methods for screening for compounds that modulate angiogenesis.

Claims

1. A substantially purified protein, consisting of a protease domain of an endotheliase protein that has catalytic activity, wherein:

the protease domain of the endotheliase is selected from the group consisting of;

a) a polypeptide consisting of the sequence of amino acid residues set forth as amino acids 320-562 of SEQ ID No. 4;

b) a polypeptide consisting of the sequence of amino acid residues set forth as amino acids 320-688 of SEQ ID No. 6; and

c) a protease domain of an endotheliase protein consisting of a sequence of amino acid residues that has at least 95% sequence identity to the sequence of amino acids set forth as amino acid residues 320-562 in SEQ IN No. 4 or amino acid residues set forth as amino acid residues 320-688 of SEQ ID No.6.

4. The protein of claim 1 that is an endotheliase 2-L.

5. The protein of claim 1 that is an endotheliase 2-S.

8. A kit, comprising a protein of claim 1 and reagents for diagnostic, therapeutic or drug screening.

10. A conjugate, comprising:

a) a protein of claim 1, and

b) a targeting agent linked to the protein directly or via a linker;

wherein the conjugate has serine protease activity.

11. The conjugate of claim 10, wherein the targeting agent permits

i) affinity isolation or purification of the conjugate;

ii) attachment of the conjugate to a surface;

iii) detection of the conjugate;

or

iv) targeted delivery to a selected tissue or cell.

13. A solid support, comprising two or more proteins of claim 1 immobilized thereon either directly or via a linker.

15. The support of claim 13, wherein the proteins comprise an array.

2. An isolated substantially purified endotheliase 1 protease domain, consisting of the sequence of amino acid residues as set forth in SEQ ID No. 2 or the sequence of amino acid residues set forth as residues 190-422 of SEQ ID No. 27, wherein the isolated purified endotheliase 1 protease domain has protease activity.

3. A substantially purified protein, comprising an endotheliase protein, wherein the endotheliase protein is an endotheliase 2 that comprises the sequence of amino acid residues set forth in SEQ ID No. 4 or 6.

14. A solid support, comprising two or more proteins of claim 3 immobilized thereon either directly or via a linker.

16. The support of claim 14, wherein the proteins comprise an array.

6. A substantially purified endotheliase protein, comprising:

the sequence of amino acids set forth in SEQ ID No. 4 or 6;

or

a sequence of amino acid residues that has at least 95% sequence identity to the sequence of amino acids set forth as SEQ ID No. 4 or 6, wherein the endotheliase protein is catalytically active.

7. A protein of claim 6 that specifically binds to an antibody that specifically binds to a protease domain of a protein comprising the sequence of amino acids set forth in SEQ ID No. 4 or 6.

9. A kit, comprising a protein of claim 6 and reagents for diagnostic, therapeutic or drug screening.

12. A conjugate, comprising an endotheliase of claim 6 and a targeting agent linked to the protein directly or via a linker, wherein the conjugate has serine protease activity.

25. The conjugate of claim 12, wherein the targeting agent permits

i) affinity isolation or purification of the conjugate;

ii) attachment of the conjugate to a surface;

iii) detection of the conjugate;

or

iv) targeted delivery to a selected tissue or cell.

17. A substantially purified endotheliase 2 that is encoded by SEQ ID No. 3 or SEQ ID No. 5.

18. A substantially purified endotheliase 2, comprising the sequence of amino acids set forth in SEQ ID No. 6 or consisting of amino acids 320-688 of SEQ ID No. 6.

19. A substantially purified endotheliase 2, comprising the sequence of amino acids set forth in SEQ ID No. 4 or consisting of amino acids 320-562 of SEQ ID No. 4.

20. A substantially purified endotheliase that has at least about 97% sequence identity with a protein that comprises the sequence of amino acids set forth in SEQ ID No. 4 or 6, wherein the substantially purified endotheliase comprises a catalytic triad.

21. A conjugate, comprising:

a) an endotheliase protein of claim 20, and

b) a targeting agent linked to the protein directly or via a linker;

wherein the conjugate has serine protease activity.

24. The conjugate of claim 21, wherein the targeting agent permits

i) affinity isolation or purification of the conjugate;

ii) attachment of the conjugate to a surface;

iii) detection of the conjugate;

or

iv) targeted delivery to a selected tissue or cell.

22. An endotheliase protein, wherein the protease domain comprises the sequence of amino acids set forth in amino acids 321-562 of SEQ ID No. 4.

23. A substantially purified isolated polypeptide, consisting of an endotheliase protease domain that has at least 95% sequence identity with the sequence of amino acids set forth in SEQ ID No. 2 or amino acids 190-422 of SEQ ID No. 27 or a contiguous portion thereof that exhibits protease activity.

26. A conjugate, comprising:

a) a polypeptide of claim 23, and

b) a targeting agent linked to the protein directly or via a linker;

wherein the conjugate has serine protease activity.

27. The conjugate of claim 26, wherein the targeting agent permits

i) affinity isolation or purification of the conjugate;

ii) attachment of the conjugate to a surface;

iii) detection of the conjugate;

or

iv) targeted delivery to a selected tissue or cell.

28. A kit, comprising a polypeptide of claim 23 and reagents for diagnostic, therapeutic or drug screening.

29. A solid support, comprising two or more polypeptides of claim 23 immobilized thereon either directly or via a linker.

30. A substantially purified protein, comprising the sequence of amino acid residues set forth in SEQ ID NO. 4 or 6.

31. A substantially purified protein of claim 30, consisting of the sequence of amino acid residues set forth in SEQ ID NO. 4 or 6.

32. A substantially purified protein, comprising the sequence of amino acid residues set forth in SEQ ID NO. 4.